Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322036 · ClinicalTrials.gov registry record · Phase 3
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
A Phase 3 study, sponsored by Myrexis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT00322036 is a Phase 3 study that was terminated before completion, run by Myrexis. The registered enrollment target is 800 participants.
The verdict
NCT00322036, a Phase 3 study, was terminated before completion, sponsored by Myrexis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.
Interventions
- DRUG MPC-7869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322036
The ClinicalTrials.gov registry entry for NCT00322036 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MPC-7869 is the first listed.
NCT00322036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322036 about?
NCT00322036 is a clinical study titled "Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's". This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved me...
What is the current status of trial NCT00322036?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2006-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00322036?
The interventions under investigation include: MPC-7869 (DRUG).
Who is sponsoring clinical trial NCT00322036?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.